They have to get direct contracts with each entity or get coverage through third party payers(Medicare/Medicaid/Champus/Tricare) which is time consuming. Problem is more complicated due to Covid. I am not suggesting progress can't be made even under challenging circumstances but that takes money. No S-1, not a lot of money without dealing with loan sharks/convertible notes.
What is going on with the SEC and Generex's S-1 review?
(2)
(0)
Generex Biotechnology Corp. (GNBTQ) Stock Research Links